North America Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity

Bio-defence is a combination of various processes and systems put in place by customs agents, bioscience laboratories, and other professionals to prevent the use of dangerous pathogens and toxins. Biodefense uses medical procedures to protect people against bioterrorism. The purposeful release of viruses, bacteria, or other organisms to cause sickness or death is referred to as a bioterrorism. North America biodefense market is expected to grow by 5.3% annually in the forecast period and reach $10.07 billion by 2030 amid the COVID-19 pandemic. The rise in naturally occurring epidemics and favourable government initiatives are the main drivers of the biodefense market's expansion. In the upcoming years, expansion of the market is projected to be hampered by restraint factors such the restricted reach of biodefense organisations. On the other hand, growing technological adoption is anticipated to favourably affect the expansion of the North American biodefense market in the years to come.The U.S. government is taking numerous efforts for the characterization of threat, risk assessment, medical countermeasures, detection, and surveillance of infectious disease along with laboratory protection from accidental exposures. Similarly, government is also taking initiatives for the awareness among large population base regarding bioterrorism incidences majorly in developed countries. Infections that spread from person to person, from animal to human, via the environment or through other media typically produce disease outbreaks. Infections that have recently manifested in a population and are expanding quickly or pose a threat to do so soon are considered emerging infectious diseases. In its 2007 report, the World Health Organization issued a warning that infectious illnesses are spreading at an unprecedented rate. About 40 infectious diseases, including SARS, MERS, Ebola, avian flu, swine flu, zika, and most recently coronavirus, have been identified since the 1970s. Additionally, according to CDC estimates, nearly 30 million persons in the U.S. contracted influenza between 2016 and 2017. Biodefense methods, such as influenza vaccinations, help lower illness by 17% and medical visits and hospitalizations by 18 to 19%, respectively. The spread of Ebola and Zika virus infections is also probably going to have an impact on how the industry develops. For instance, as of 20 March 2020, the WHO had received reports of more than 210,000 infections related to the coronavirus outbreak, and more than 9,000 people had died as a result. Additionally, on March 18, 2020, Vaxart and Emergent BioSolutions inked a contract for the research and manufacture of the latter's experimental oral vaccine candidate for the coronavirus disease. In the past, the release of radioactive materials, biological toxins, chemical weapons like nerve gas, or pathogenic pathogens like anthrax or smallpox posed public hazards. The administration has developed different methods to stop such epidemics, For instance, the research on infectious diseases and biodefense that is funded by the National Institutes of Health (NIH) creates and maintains a base of fundamental knowledge about infectious and immune-related diseases and makes use of that knowledge to create new and better diagnostics, therapeutics, and preventative measures, such as vaccines. The US held the greatest market share in the North American biodefense market in 2019, and it is anticipated that it would expand more quickly than other countries over the forecast period. The United States is an economically developed nation with a number of well-established participants in the biotechnology industry. The U.S. military and civilian agencies' significant funding for biodefense is another important element in the region's high income share. As a result, taking into account the aforementioned factors, the biodefense market is anticipated to expand significantly in the US during the course of the projected year.

The COVID-19 pandemic had a favorable influence on the biodefense market. The COVID-19 pandemic demonstrates how catastrophic biological events may result in significant human and economic loss, necessitating a proactive response from numerous government and nonfederal agencies. There are several reasons to believe that the COVID-19 pandemic is an intentional act of bioterrorism. COVID-19 promises a huge potential for investment and income redistribution, similar to the swine flu epidemic of 2008-2009, when billions were created by major companies across the globe.

Highlighted with 25 tables and 37 figures, this 103-page report “North America Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. 

In-depth qualitative analyses include identification and investigation of the following aspects:
   • Market Structure 
   • Growth Drivers 
   • Restraints and Challenges
   • Emerging Product Trends & Market Opportunities
   • Porter’s Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country. 

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

By Product type  
     • Vaccines
            • Anthrax
            • Smallpox
            • Botulism
            • Nuclear/Radiation
            • E-Bola
            • Zika
            • Other Vaccines
     • Biothreat Detection Devices
            • Detectors/Triggering Devices
            • Assays and Reagents
            • Samplers
            • Identifiers
     •Antibiotics
     • Masks
     • Other Products 

By Sales Channel
     • Online Sales
     • Offline Sales

By Application
     • Military
     • Civilian

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

By Geography
  • U.S.
  • Canada
  • Mexico

For each aforementioned country, detailed analysis and data for annual revenue are available for 2020-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.

Specifically, potential risks associated with investing in North America biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request): 
Achaogen, Inc., Alexeter Technologies LLC, Alnylam Pharmaceuticals, Inc., Altimmune, Inc., Bavarian Nordic AS, BioFactura, Inc., Cleveland Biolabs, Inc., Dynavax Technologies Inc, Dynport Vaccine Company LLC (DVC), Elusys Therapeutics, Inc., Emergent BioSolutions Inc, General Dynamics Corp., GlaxoSmithKline Plc, Ichor Medical Systems, Mediimmune (AstraZeneca), Nanotherapeutics, Inc., Ology Bioscience, PathSensors Inc, Pluristem Therapeutics, Sanofi Pasteur Ltd., SIGA Technologies, Inc., Soligenix, Inc., Xoma Corporation, 

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)